Xiaojiang Duan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaojiang Duan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Bingqi Dong
Department of Gastrointestinal Surgery, Peking University First Hospital, Xicheng District, Beijing, China
1 shared publication- Difei Lu
Department of Endocrinology Peking University First Hospital Beijing China
1 shared publication - Guangyu Zhao
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
1 shared publication - Haoyu Weng
Department of Cardiology, Peking University First Hospital, Beijing, China
1 shared publication Hongjin Liu
Department of Gastrointestinal Surgery, Peking University First Hospital, Xicheng District, Beijing, China
1 shared publication- Jianhua Zhang
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 30 December 2025
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 67 (3) , 471-480
Construction and Evaluation of Guanylyl Cyclase C–Specific Antibody for Noninvasive Diagnosis and Targeted Therapy of Colorectal Cancer
Colorectal cancer (CRC) remains the leading cause of cancer mortality worldwide despite therapeutic advances. Guanylyl cyclase C (GUCY2C), an intestinal epithelial receptor, is emerging as a promising diagnostic and therapeutic target for CRC. Thus, we are interested in developing a monoclonal antibody probe targeting GUCY2C for both in vitro and in vivo diagnosis and treatment of CRC. Methods: The GUCY2C-specific monoclonal antibody, PR15-7, was generated by hybridoma fusion. We developed [89Zr]Zr-DFO-PR15-7 for PET imaging, Cy5-PR15-7 for near-infrared fluorescence I (NIR-I) detection, and ICG-PR15-7 for NIR-II–guided surgical navigation. The therapeutic potential was evaluated using [177Lu]Lu-DOTA-PR15-7 for targeted radiotherapy. Biologic properties and antitumor activity of PR15-7 probes were evaluated in vitro and in vivo. Results: PR15-7 showed strong GUCY2C binding affinity and tumor selectivity. PR15-7 probes in antibody-based PET and NIR imaging revealed 3 times higher signal intensity in GUCY2C-positive tumors compared with controls. The NIR-II probe ICG-PR15-7 enabled precise intraoperative tumor visualization and complete resection in orthotopic models. Therapeutic administration of [177Lu]Lu-DOTA-PR15-7 significantly inhibited tumor growth, with standardized tumor volumes at 16 d being markedly smaller than those in the control groups. Conclusion: We have established both optical and radionuclide probes with PR15-7 as a versatile therapeutic strategy, providing valuable insights into targeted therapy for CRC. Visual Abstract
- 30 December 2025
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 67 (3) , 471-480
Open AccessConstruction and Evaluation of Guanylyl Cyclase C–Specific Antibody for Noninvasive Diagnosis and Targeted Therapy of Colorectal Cancer
Colorectal cancer (CRC) remains the leading cause of cancer mortality worldwide despite therapeutic advances. Guanylyl cyclase C (GUCY2C), an intestinal epithelial receptor, is emerging as a promising diagnostic and therapeutic target for CRC. Thus, we are interested in developing a monoclonal antibody probe targeting GUCY2C for both in vitro and in vivo diagnosis and treatment of CRC. Methods: The GUCY2C-specific monoclonal antibody, PR15-7, was generated by hybridoma fusion. We developed [89Zr]Zr-DFO-PR15-7 for PET imaging, Cy5-PR15-7 for near-infrared fluorescence I (NIR-I) detection, and ICG-PR15-7 for NIR-II–guided surgical navigation. The therapeutic potential was evaluated using [177Lu]Lu-DOTA-PR15-7 for targeted radiotherapy. Biologic properties and antitumor activity of PR15-7 probes were evaluated in vitro and in vivo. Results: PR15-7 showed strong GUCY2C binding affinity and tumor selectivity. PR15-7 probes in antibody-based PET and NIR imaging revealed 3 times higher signal intensity in GUCY2C-positive tumors compared with controls. The NIR-II probe ICG-PR15-7 enabled precise intraoperative tumor visualization and complete resection in orthotopic models. Therapeutic administration of [177Lu]Lu-DOTA-PR15-7 significantly inhibited tumor growth, with standardized tumor volumes at 16 d being markedly smaller than those in the control groups. Conclusion: We have established both optical and radionuclide probes with PR15-7 as a versatile therapeutic strategy, providing valuable insights into targeted therapy for CRC. Visual Abstract
- Open Access
- 23 December 2024
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (1) , 142-150
68Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling
Purpose: To investigate the diagnostic efficacy of 68Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients. Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after 68Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side. Statistical analysis was performed using SPSS 21.0. Results: The female proportion of all patients with PA was 32.4% (12/37), and the mean age was 51.3 ± 10.9 years. Patients with bilateral adrenal mass accounted for 54.1% (20/37), and 10 of them (27.0%) had adrenal hyperplasia or adrenal nodules ≤ 1.0 cm. In all 37 patients, the sensitivity, specificity and accuracy of 68Ga-pentixafor PET/CT in distinguishing lateralization by visualization were 89.3%, 77.8% and 86.5%, respectively. The area under the ROC curve for detecting positive lateralization based on the value of 68Ga-pentixafor SUVmax was 0.750 (95%CI 0.578–0.922, p = 0.026). The optimum SUVmax cut-off value was 6.86, with the sensitivity of 78.6%, specificity of 66.7%, and accuracy of 78.4%. Defining SUV ratio as SUVmax/SUV of contralateral adrenal gland, the area under the ROC curve for identifying lateralization based on the SUV ratio was 0.710 (95%CI 0.500–0.921, p = 0.061). The optimum SUV ratio cut-off was 2.40, with the sensitivity of 60.7%, specificity of 88.9%, and accuracy of 67.6%. The consistency of 68Ga-pentixafor PET/CT with AVS was of no significant difference between patients with bilateral adrenal lesions (80.0%, 16/20) and unilateral lesion (94.1%, 16/17; p = 0.737), and no significance was revealed in the consistency between patients with adrenal hyperplasia or adrenal lesion of diameter ≤ 1 cm (81.8%, 9/11) and those with adrenal lesions > 1 cm (88.5%, 23/26; p = 0.884). Conclusions: 68Ga-pentixafor PET/CT showed at least 80% consistency for the lateralization in patients with PA compared with AVS, even in those presented with bilateral adrenal hyperplasia. Visual analysis exhibited better diagnostic efficacy compared with SUVmax or SUVmax/SUV of the contralateral adrenal gland.( ChiCTR2300073049. Registered 30 June 2023. Retrospectively registered)
- 23 December 2024
- Published by Springer Nature in Molecular Imaging and Biology
- Vol. 27 (1) , 142-150
Open Access68Ga-pentixafor PET/CT Is a Supplementary Method for Primary Aldosteronism Subtyping Compared with Adrenal Vein Sampling
Purpose: To investigate the diagnostic efficacy of 68Ga-pentixafor positron emission tomography/computed tomography (PET/CT) in primary aldosteronism (PA) subtyping and lateralization of aldosterone secretion in PA patients. Procedures: 37 patients who were diagnosed with PA, were prospectively enrolled in the study, and underwent adrenal vein sampling (AVS) after 68Ga-pentixafor PET/CT was conducted. Lateralization index (LI), defined as aldosterone/cortisol ratio in the dominant side to the contralateral adrenal vein when bilateral adrenal vein catheterization succeeded, and the aldosterone/cortisol ratio in the left adrenal vein to IVC (LAV/IVC) when the catheterization of right adrenal vein failed, were applied to determine lateralization side. Statistical analysis was performed using SPSS 21.0. Results: The female proportion of all patients with PA was 32.4% (12/37), and the mean age was 51.3 ± 10.9 years. Patients with bilateral adrenal mass accounted for 54.1% (20/37), and 10 of them (27.0%) had adrenal hyperplasia or adrenal nodules ≤ 1.0 cm. In all 37 patients, the sensitivity, specificity and accuracy of 68Ga-pentixafor PET/CT in distinguishing lateralization by visualization were 89.3%, 77.8% and 86.5%, respectively. The area under the ROC curve for detecting positive lateralization based on the value of 68Ga-pentixafor SUVmax was 0.750 (95%CI 0.578–0.922, p = 0.026). The optimum SUVmax cut-off value was 6.86, with the sensitivity of 78.6%, specificity of 66.7%, and accuracy of 78.4%. Defining SUV ratio as SUVmax/SUV of contralateral adrenal gland, the area under the ROC curve for identifying lateralization based on the SUV ratio was 0.710 (95%CI 0.500–0.921, p = 0.061). The optimum SUV ratio cut-off was 2.40, with the sensitivity of 60.7%, specificity of 88.9%, and accuracy of 67.6%. The consistency of 68Ga-pentixafor PET/CT with AVS was of no significant difference between patients with bilateral adrenal lesions (80.0%, 16/20) and unilateral lesion (94.1%, 16/17; p = 0.737), and no significance was revealed in the consistency between patients with adrenal hyperplasia or adrenal lesion of diameter ≤ 1 cm (81.8%, 9/11) and those with adrenal lesions > 1 cm (88.5%, 23/26; p = 0.884). Conclusions: 68Ga-pentixafor PET/CT showed at least 80% consistency for the lateralization in patients with PA compared with AVS, even in those presented with bilateral adrenal hyperplasia. Visual analysis exhibited better diagnostic efficacy compared with SUVmax or SUVmax/SUV of the contralateral adrenal gland.( ChiCTR2300073049. Registered 30 June 2023. Retrospectively registered)